UNSPSC 51313405: Carbinoxamine or rotoxamine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 982A7M02H5, chemically known as pyridine, 2-(p-chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)- but generally known as carbinoxamine, which bears US NIH Compound Identifier 2564. Carbinoxamine most often comes in base and maleate forms. European Medicines Agency schedules Carbinoxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06128MIG.

UNSPSC 51313405 Carbinoxamine or rotoxamine is a Commodity code for pharmaceutical active ingredients and finished products that state and local governments procure primarily through health departments, emergency response programs, and multistate cooperative purchasing alliances. Recent solicitations under this code show state and local buyers acquiring naloxone (an opioid antagonist), safe drug deactivation systems, and generic multi-source pharmaceuticals for community health initiatives, emergency preparedness, and medicaid-eligible populations. Issuing bodies include county health departments, state health and human services commissions, and cooperative purchasing consortia representing multiple jurisdictions; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and the Texas Health and Human Services Commission appear as active procurers. Work solicited ranges from emergency-response medications (naloxone kits) to broad-based generic pharmaceutical supply agreements serving state and local health programs.

Geographically, recent activity concentrates in Florida, Minnesota, Texas, and Oregon, with the MMCAP cooperative extending reach across multiple participating states. Representative opportunities include Seminole County, Florida's competitive IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023) with quarterly deliveries to the county community health building; the Minnesota Department of Administration's RFP through MMCAP for generic multi-source pharmaceuticals and OTC products to authorized wholesalers (responses due March 26, 2026); and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (April 3, 2026). Contracts typically require compliance with cGMP, the Drug Supply Chain Security Act, E-Verify, workers' compensation insurance, and commercial general liability coverage. Initial contract terms run two years with renewal or extension options; MMCAP imposes a 3 percent administrative fee on purchases and performance penalties for late reporting or missed timelines.